Compare IBRX & AN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | AN |
|---|---|---|
| Founded | 2014 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.4B |
| IPO Year | 2015 | 1995 |
| Metric | IBRX | AN |
|---|---|---|
| Price | $7.24 | $208.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $12.57 | ★ $244.33 |
| AVG Volume (30 Days) | ★ 9.4M | 356.1K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | 0.71 |
| EPS | N/A | ★ 5.85 |
| Revenue | $113,288,000.00 | ★ $27,631,400,000.00 |
| Revenue This Year | $88.59 | $4.32 |
| Revenue Next Year | $131.15 | $2.89 |
| P/E Ratio | ★ N/A | $37.31 |
| Revenue Growth | ★ 668.31 | 3.24 |
| 52 Week Low | $1.95 | $176.62 |
| 52 Week High | $12.43 | $235.81 |
| Indicator | IBRX | AN |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 50.91 |
| Support Level | $6.69 | $202.40 |
| Resistance Level | $8.46 | $218.10 |
| Average True Range (ATR) | 0.42 | 8.32 |
| MACD | -0.09 | 0.99 |
| Stochastic Oscillator | 38.93 | 26.53 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
AutoNation is the second-largest automotive dealer in the United States, with 2025 revenue of $27.6 billion and over 240 dealerships, plus 52 collision centers. The firm also has 26 AutoNation USA used-vehicle stores, a captive lender, four auction sites, and three parts distributors across 20 states primarily in Sunbelt metropolitan areas. New-vehicle sales account for nearly half of revenue; the company also sells used vehicles, parts, and repair services as well as auto financing. The company (formerly Republic Industries) divested its waste management unit (Republic Services) in 1999 and its car rental businesses (ANC Rental) in 2000. Wayne Huizenga founded the company in the 1990s to bring the rollup acquisition strategy to auto retailing, which has proved to be a smart move.